The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Bregua Corporation, startups are often financed by Avalon Ventures, Torrey Pines Investment, WuXi Healthcare Ventures. The meaningful sponsors for the fund in investment in the same round are Avalon Ventures, WuXi Healthcare Ventures, Vivo Capital.
Among the various public portfolio startups of the fund, we may underline Acousia Therapeutics, Fortis Therapeutics, Avelas Biosciences Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Health Care. The fund has exact preference in a number of founders of portfolio startups.
The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2016. The fund is generally included in less than 2 deals every year.
Related Funds
| Fund Name | Location |
| A.T.E. Chandra Foundation | India, Maharashtra, Mumbai |
| Changjianghui Jijin | China, Shanghai |
| DMG Media | England, London, United Kingdom |
| Forec | - |
| Morale Capital | Chaoyang, China, Liaoning |
| Morningstar Japan | Chiba Prefecture, Japan, Tateyama |
| SLO Seed Ventures | California, San Luis Obispo, United States |
| WVV Capital | Milwaukee, United States, Wisconsin |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Janux Therapeutics | $125M | 20 Apr 2021 | La Jolla, California, United States | ||
Fortis Therapeutics | $40M | 29 Mar 2021 | San Diego, California, United States | ||
Janux Therapeutics | $56M | 03 Mar 2021 | La Jolla, California, United States | ||
Acousia Therapeutics | $11M | 14 May 2018 | Baden-Württemberg | ||
Fortis Therapeutics | $18M | 27 Sep 2016 | San Diego, California, United States | ||
Avelas Biosciences | $20M | 18 Aug 2016 | San Diego, California, United States |
– Fortis Therapeutics from San Diego is developing novel antibody-drug conjugate FOR46 for late-stage multiple myeloma and metastatic castration-resistant prostate cancer.
– The company closed a $40m Series A financing cofunded by Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, Vivo Capital, the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Foundation (MMRF), and Fulcrum 2020, LLC.
– The new investment will be used to advance FOR46 in clinical trials for the treatment of relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Janux Therapeutics | $125M | 20 Apr 2021 | La Jolla, California, United States | ||
Fortis Therapeutics | $40M | 29 Mar 2021 | San Diego, California, United States | ||
Janux Therapeutics | $56M | 03 Mar 2021 | La Jolla, California, United States | ||
Acousia Therapeutics | $11M | 14 May 2018 | Baden-Württemberg | ||
Fortis Therapeutics | $18M | 27 Sep 2016 | San Diego, California, United States | ||
Avelas Biosciences | $20M | 18 Aug 2016 | San Diego, California, United States |
